BCG and protection against Mycobacterium tuberculosis infection [2]

Lancet

Volumn 367, Issue 9508, 2006, Pages 391-392

  Lalvani, A ^a   Bakir, M ^b   Millington, K A ^a   Dosanjh, D ^a   Soysal, A ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ISONIAZID;

BCG VACCINATION; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; LETTER; MATHEMATICAL MODEL; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SERODIAGNOSIS; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 31844456845     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68129-4     Document Type: Letter

References (5)

1. C Lienhardt, A Zumla BCG: the story continues Lancet 366 2005 1414 1416
2. A Soysal, KA Millington, M Bakir Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study Lancet 366 2005 1443 1451
3. H Shams, SE Weis, P Klucar Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection Am J Respir Crit Care Med 172 2005 1161 1168
4. K Ewer, J Deeks, L Alvarez Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak Lancet 361 2003 1168 1173
5. A Lalvani, AA Pathan, H Durkan Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells Lancet 357 2001 2017 2021